Gilead Sciences (0QYQ) Stock Overview

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details

0QYQ fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 53.4% below our estimate of its fair value

Earnings are forecast to grow 45.4% per year

Risk Analysis

Has a high level of debt

Dividend of 2.25% is not well covered by earnings

0QYQ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,082 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

436,082 investors already sharing narratives

View all narratives

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gilead Sciences
Historical stock prices
Current Share Price	US$145.72
52 Week High	US$157.79
52 Week Low	US$108.50
Beta	0.35
1 Month Change	6.72%
3 Month Change	16.38%
1 Year Change	24.45%
3 Year Change	87.72%
5 Year Change	104.49%
Change since IPO	70.51%

Recent updates

Shareholder Returns

	0QYQ	GB Biotechs	GB Market
7D	-3.4%	-0.08%	-0.7%
1Y	24.5%	-23.3%	16.1%

Return vs Industry: 0QYQ exceeded the UK Biotechs industry which returned -23.3% over the past year.

Return vs Market: 0QYQ exceeded the UK Market which returned 16.1% over the past year.

Price Volatility

Is 0QYQ's price volatile compared to industry and market?
0QYQ volatility
0QYQ Average Weekly Movement	3.6%
Biotechs Industry Average Movement	6.8%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0QYQ has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QYQ's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	17,000	Dan O'Day	www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
0QYQ fundamental statistics
Market cap	US$180.60b
Earnings (TTM)	-US$3.24b
Revenue (TTM)	US$30.46b

5.9x

P/S Ratio

-55.7x

P/E Ratio

Is 0QYQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QYQ income statement (TTM)
Revenue	US$30.46b
Cost of Revenue	US$6.21b
Gross Profit	US$24.25b
Other Expenses	US$27.49b
Earnings	-US$3.24b

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.61
Gross Margin	79.60%
Net Profit Margin	-10.64%
Debt/Equity Ratio	223.5%

How did 0QYQ perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

-123%

Payout Ratio

Does 0QYQ pay a reliable dividends?

See 0QYQ dividend history and benchmarks

When do you need to buy 0QYQ by to receive an upcoming dividend?
Gilead Sciences dividend dates
Ex Dividend Date	Sep 15 2026
Dividend Pay Date	Sep 29 2026
Days until Ex dividend	4 days
Days until Dividend pay date	18 days

Does 0QYQ pay a reliable dividends?

See 0QYQ dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/10 13:15
End of Day Share Price	2026/09/09 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Brian Skorney	Baird
James Birchenough	Barclays

Gilead Sciences (0QYQ) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Gilead Sciences, Inc. Competitors

Genus

AstraZeneca

GSK

Oxford Biomedica

Price History & Performance

Recent News & Updates

Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv

Upcoming dividend of US$0.82 per share

Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV

Gilead Sciences, Inc. Receives European Commission Approval for Trodelvy Plus Pembrolizumab in First-Line Metastatic Triple-Negative Breast Cancer

Second quarter dividend of US$0.82 announced

Second quarter 2026 earnings released: US$8.44 loss per share (vs US$1.57 profit in 2Q 2025)

Recent updates

Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv

Upcoming dividend of US$0.82 per share

Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV

Gilead Sciences, Inc. Receives European Commission Approval for Trodelvy Plus Pembrolizumab in First-Line Metastatic Triple-Negative Breast Cancer

Second quarter dividend of US$0.82 announced

Second quarter 2026 earnings released: US$8.44 loss per share (vs US$1.57 profit in 2Q 2025)

Gilead Sciences, Inc. Recommends Trodelvy Plus Keytruda In PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. to Report Q2, 2026 Results on Aug 04, 2026

Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Dynamic Index

Gilead Sciences, Inc. Announces FDA Approval Of Trodelvy for First-Line Treatment Of Metastatic Triple-Negative Breast Cancer

Gilead Sciences Announces European Commission Approval for Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

Gilead Sciences Receives Fda Acceptance for Supplemental New Drug Application for Once-Weekly Oral Yeztugo for Hiv Prevention

Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment

Upcoming dividend of US$0.82 per share

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others.

Gilead Sciences Announces Statistically Significant Composite ALP Normalization With Livdelzi In Phase 3 IDEAL Trial In Primary Biliary Cholangitis

Gilead Sciences Shares Interim Phase 3 ASSURE Data Demonstrating High And Sustained ALP Normalization With Livdelzi (Seladelpar) In People With Primary Biliary Cholangitis

First quarter dividend of US$0.82 announced

First quarter 2026 earnings released: EPS: US$1.63 (vs US$1.06 in 1Q 2025)

Gilead Sciences, Inc. Receives U.S. FDA Priority Review For Once-Daily HIV Treatment Bictegravir Plus Lenacapavir

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of 77.2% stake in Arcellx, Inc. (NasdaqGS:ACLX) from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others.

Gilead Sciences, Inc. to Report Q1, 2026 Results on May 07, 2026

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Tubulis GmbH from a group of shareholders for $5 billion.

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. (SEHK:2162) and others for $2.2 billion.

Gilead Sciences, Inc., Annual General Meeting, Apr 30, 2026

Upcoming dividend of US$0.82 per share

Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026

Gilead Sciences, Inc. to Present New Hiv Treatment and Prevention Data At Croi 2026, with A Focus on Expanding Options

Fourth quarter dividend increased to US$0.82

New minor risk - Financial position

Full year 2025 earnings released: EPS: US$6.84 (vs US$0.39 in FY 2024)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2026

Fda Approves Label Update for Kite's Yescarta®? for Relapsed/Refractory Primary Central Nervous System Lymphoma

Gilead Sciences, Inc. to Report Q4, 2025 Results on Feb 10, 2026

Gilead Sciences, Inc. Announces New England Journal of Medicine Publishes Phase 3 ASCENT-04/KeyNOTE-D19 Results Supporting Trodelvy®? Plus Keytruda®? as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences, Inc. Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Effective December 18, 2025

Gilead Sciences, Inc. Announces Positive Topline Results from the Phase 3 ARTISTRY-2 Trial

Upcoming dividend of US$0.79 per share

Deborah H. Telman to No Longer Serve as Executive Vice President, Corporate Affairs and General Counsel of Gilead Sciences, Inc. as of December 5, 2025

Gilead Sciences, Inc. Joins Partners for Delivery of First Shipments of Breakthrough Twice-Yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Gilead Sciences, Inc.'s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ART-1 Trial

Gilead Sciences, Inc. Provides Update on Phase 3 ASCENT-07 Study

Third quarter dividend of US$0.79 announced

Gilead Sciences, Inc. announces Quarterly dividend, payable on December 30, 2025

Third quarter 2025 earnings released: EPS: US$2.46 (vs US$1.01 in 3Q 2024)

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2025

Gilead Sciences, Inc. to Showcase Interim Long-Term Efficacy Data for Livdelzi (Seladelpar) in Primary Biliary Cholangitis (Pbc) and Investigational Bulevirtide in Chronic Hepatitis Delta

Gilead Sciences, Inc. Receives Health Canada Approval for the Treatment of Primary Biliary Cholangitis

Gilead Sciences, Inc. to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025

Gilead Presents New Hiv Research Data At EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care with New Data At Esmo 2025

Gilead Sciences, Inc. to Report Q3, 2025 Results on Oct 30, 2025

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces European Commission Authorizes Twice-Y Early Yeytuo (Lenacapavir) for HIV Prevention

Second quarter dividend of US$0.79 announced

Second quarter 2025 earnings released: EPS: US$1.57 (vs US$1.29 in 2Q 2024)

Gilead Sciences, Inc. (NasdaqGS:GILD) announces an Equity Buyback for $6,000 million worth of its shares.

Gilead Receives Positive CHMP Opinions Under Accelerated Review from European Medicines Agency for Twice-Yearly HIV PrEP Option in the European Union

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention At Ias 2025

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approves Yeztugo (Lanacapavir) as Pre-Exposure Prophylaxis

Upcoming dividend of US$0.79 per share

Gilead Sciences, Inc. Announces Trodelvy Plus Keytruda®? Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer